Biodexa Pharmaceuticals
BDRX
10 hedge funds and large institutions have $136K invested in Biodexa Pharmaceuticals in 2024 Q2 according to their latest regulatory filings, with 7 funds opening new positions, 1 increasing their positions, 2 reducing their positions, and 0 closing their positions.
334% more capital invested
Capital invested by funds: $31.2K → $136K (+$104K)
233% more funds holding
Funds holding: 3 → 10 (+7)
0% less ownership
Funds ownership: 0% → 0% (-0%)
50% less repeat investments, than reductions
Existing positions increased: 1 | Existing positions reduced: 2
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
VF
Virtu Financial
New York
|
+$38K |
| 2 |
Citadel Advisors
Miami,
Florida
|
+$35.4K |
| 3 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$31.4K |
| 4 |
TSS
Two Sigma Securities
New York
|
+$21K |
| 5 |
GSC
Ground Swell Capital
Folly Beach,
South Carolina
|
+$13.1K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
GI
GAMMA Investing
Foster City,
California
|
-$7.86K |
| 2 |
Bank of America
Charlotte,
North Carolina
|
-$3.93K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
VF
1
Virtu Financial
New York
| $32K | +$38K | +29 | New |
|
|
2
Citadel Advisors
Miami,
Florida
| $30K | +$35.4K | +27 | New |
|
|
3
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
| $27K | +$31.4K | +24 | New |
|
|
TSS
4
Two Sigma Securities
New York
| $18.4K | +$21K | +16 | New |
|
|
GSC
5
Ground Swell Capital
Folly Beach,
South Carolina
| $11.7K | +$13.1K | +10 | New |
|
6
UBS Group
Zurich,
Switzerland
| $8.96K | +$7.86K | +6 | +300% |
|
|
GI
7
GAMMA Investing
Foster City,
California
| $3.49K | -$7.86K | -6 | -67% |
|
8
RhumbLine Advisers
Boston,
Massachusetts
| $2.42K | +$2.62K | +2 | New |
|
|
CIM
9
Contravisory Investment Management
Norwell,
Massachusetts
| $896 | +$1.31K | +1 | New |
|
|
10
Bank of America
Charlotte,
North Carolina
| $769 | -$3.93K | -3 | -75% |
|
11
Morgan Stanley
New York
| $14 | – | – | – |
|
|
IC
12
Innealta Capital
Austin,
Texas
| $11 | – | – | – |
|
|
HT
13
Headlands Technologies
Chicago,
Illinois
| $7 | – | – | – |
|
BDRX Hedge Fund Activity: Q2 2024 in Review
10 of the 6,929 institutional investors tracked by Wall St. Rank reported a position in Biodexa Pharmaceuticals (BDRX) for Q2 2024, worth a combined $136K — up 334% from $31.2K a quarter earlier.
Buyers outnumbered sellers: 7 funds opened new BDRX positions and 0 closed out — a net gain of 7 holders — while 1 added to existing stakes and 2 trimmed.
The largest buyer was Virtu Financial, opening a new position worth an estimated $38K. The largest seller was GAMMA Investing, cutting an estimated $7.86K.
- 10 institutional investors held Biodexa Pharmaceuticals (BDRX) as of Q2 2024, up from 3 in Q1 2024.
- Funds reported $136K of Biodexa Pharmaceuticals stock for Q2 2024, up 334% quarter-over-quarter.
- 7 funds opened new Biodexa Pharmaceuticals positions in Q2 2024 and 0 closed out, a net change of +7 holders.
- The largest Biodexa Pharmaceuticals buyer in Q2 2024 was Virtu Financial, an estimated $38K added.
- The largest Biodexa Pharmaceuticals seller in Q2 2024 was GAMMA Investing, an estimated $7.86K sold.
Based on aggregated 13F filings for Q2 2024.